Imrnw Stock News

Immuron <> ADRs have approached the highest level in more than three months after announcing a cash refund of approximately AUD 306K from the Australian government.The refund was…

Immuron (IMRN) has been granted a European Patent for compositions and methods for treating travelers diarrhea

Immuron Limited (NASDAQ: Full story available on Benzinga.com

Shares of Immuron Ltd. rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading volume spiked to 1.3 million shares, compared with the full-day average of about 60,500. The award is aimed at testing the efficacy of a single larger dose regimen of Travelan for the treatment of moderate to severe diarrhea upon challenge with enterotoxigenic Escherichia coli (ETEC). "This new project expands our clinical development program and represents the first of several significant clinical trials which the Company expects to undertake with the US Military in 2022," said Immuron Chief Executive JErry Kanellos. "The new funding is testament to the value proposition our hyperimmune bovine polyclonal colostrum technology offers to benefit the US Military as well as the civilian international travelling population.

Immuron (IMRN) soars 44.9% premarket after announcing the funding of a new research agreement with the U.S Department of Defense (DoD).IMRN is awarded A$4.8M ($3.43M) funding